methyl 4-O-(2,3,6-tri-O-benzyl-4-O-trifluoromethylsulfonyl-α-D-galactopyranosyl)-2,3,6-tri-O-benzyl-α-D-glucopyranoside | 127243-57-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 4-O-(2,3,6-tri-O-benzyl-4-O-trifluoromethylsulfonyl-α-D-galactopyranosyl)-2,3,6-tri-O-benzyl-α-D-glucopyranoside
• 英文别名: METHYL 4-O-(2,3,6-TRI-O-BENZYL-4-O-TRIFLUOROMETHYLSULFONYL-alpha-D-GALACTOPYRANOSYL)-2,3,6-TRI-O-BENZYL-alpha-D-GLUCOPYRANOSIDE；[(2R,3S,4R,5R,6R)-6-[(2R,3R,4S,5R,6S)-6-methoxy-4,5-bis(phenylmethoxy)-2-(phenylmethoxymethyl)oxan-3-yl]oxy-4,5-bis(phenylmethoxy)-2-(phenylmethoxymethyl)oxan-3-yl] trifluoromethanesulfonate
• CAS: 127243-57-6
• 化学式: C₅₆H₅₉F₃O₁₃S
• 分子量: 1029.14
• InChiKey: GMWRFOBVHKLVGX-FSFZQLGJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.8
• 重原子数：
  73
• 可旋转键数：
  25
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  144
• 氢给体数：
  0
• 氢受体数：
  16

反应信息

• 作为产物：
  描述：

  吡啶 、 三氟甲磺酸酐 、 methyl 2,3,6-tri-O-benzyl-4-O-(2,3,6-tri-O-benzyl-α-D-galactopyranosyl)-α-D-glucopyranoside 、 triflate methyl 4-O-(2,3,6-tri-O-benzyl-4-O-tri-fluoromethylsulfonyl-alpha-D-galactopyranosyl)-2,3,6-tri-O-benzyl-alpha-D-glucopyranoside 在 水 、 Sodium sulfate-III 作用下， 以 二氯甲烷 为溶剂， 反应 1.75h， 生成 methyl 4-O-(2,3,6-tri-O-benzyl-4-O-trifluoromethylsulfonyl-α-D-galactopyranosyl)-2,3,6-tri-O-benzyl-α-D-glucopyranoside
  参考文献：
  名称：

  .alpha.-glucosidase inhibitors

  摘要：

  本发明涉及1-脱氧诺吉霉素的新型N-衍生物，涉及其制备过程及其最终应用，特别是涉及其在糖尿病治疗中的应用。

  公开号：

  US05157116A1

文献信息

• Novel alpha-glucosidase inhibitors
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0389723A1

  公开（公告）日：1990-10-03

  This invention relates to novel N-derivatives, of 1,4-di-­deoxy-1,4-imino-L-arabinitol (I), to the processes for their preparation and to their end-use applications, particularly as to their use in the treatment of diabetes. wherein n is zero, one or two, and R is a glycosyl or etherified or acylated glycosyl radical containing from 1 to 3 hexose or pentose units, said glycosyl radical optionally bearing an ether or ester derivative of the hydroxyl moiety located on the anomeric carbon atom.

  本发明涉及新颖的1,4-二脱氧-1,4-亚氨基-L-阿拉伯糖醇（I）的N-衍生物，涉及其制备方法及其最终用途，特别是作为治疗糖尿病的用途。 其中n为0、1或2，R为含有1至3个己糖或戊糖单元的糖基或醚化或酰化的糖基基团，所述糖基基团任选地在其异头碳原子上的羟基部分带有醚或酯衍生物。
• Novel alpha-Glucosidase inhibitors
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0344383A1

  公开（公告）日：1989-12-06

  This invention relates to novel N-derivatives of 1-deoxy-nojirimyoin, to the processes for their preparation and to their end-use applications, particularly as to their use in the treatment of diabetes.

  本发明涉及 1-脱氧野尻yoin的新型 N-衍生物、其制备工艺及其最终用途，特别是在治疗糖尿病方面的应用。
• Novel Alpha-glucosidase inhibitors
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0345104A2

  公开（公告）日：1989-12-06

  This invention relates to novel N-derivatives of 1-deoxy-nojirimycin (1) to the processes for their preparation and to their end-use applications, particularly as to their use in the treatment of diabetes. wherein n is zero, one or two, and R is a glycosyl or etherified or acylated glycosyl radical containing from 1 to 3 hexose or pentose units, said glycosyl radical optionally bearing an ether or ester derivative of the hydroxyl moeity located on the anomeric carbon atom of the terminal hexose or pentose moeity.

  本发明涉及 1-脱氧-野尻霉素（1）的新型 N 衍生物及其制备工艺和最终应用，特别是在糖尿病治疗中的应用。 其中 n 为 0、1 或 2，R 为含有 1 至 3 个己糖或戊糖单元的糖基或醚化或酰化的糖基，所述糖基任选带有位于末端己糖或戊糖单元的异构碳原子上的羟基的醚或酯衍生物。
• Alpha-glucosidase inhibitors
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0422975B1

  公开（公告）日：1994-07-27
• NOVEL ALPHA-GLUCOSIDASE INHIBITORS
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0532668B1

  公开（公告）日：1995-11-15